|
176 Companies |
|
232 Products |
|
232 Products |
|
108 Mechanisms of Action |
|
9 Trials |
|
1978 News |
|
| «12345678910111213...4142» |
- || RG7775 / Roche
Trial primary completion date, IO biomarker, Metastases: A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. (clinicaltrials.gov) - Jul 19, 2017
P1, N=68, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2017 --> May 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Jul 17, 2017
P2, N=19, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: May 2017 --> May 2018 N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015
- | cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date: Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=9, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015 Terminated --> Active, not recruiting | Trial primary completion date: May 2011 --> May 2020
- |||| ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial completion: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 13, 2017
P1/2, N=53, Completed, Sponsor: BioMed Valley Discoveries, Inc
Terminated --> Active, not recruiting | Trial primary completion date: May 2011 --> May 2020 Recruiting --> Completed
- || guadecitabine (SGI-110) / Otsuka
Trial primary completion date: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (clinicaltrials.gov) - Jul 12, 2017
P2, N=56, Active, not recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Recruiting --> Completed Trial primary completion date: Jul 2015 --> Feb 2016
- | Vonjo (pacritinib) / SOBI
Trial suspension: Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (clinicaltrials.gov) - Jul 7, 2017
P1, N=60, Suspended, Sponsor: Bhavana Bhatnagar
Trial primary completion date: Jul 2015 --> Feb 2016 Recruiting --> Suspended
- navtemadlin (KRT-232) / Kartos Therap
Trial primary completion date, Combination therapy: A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 2, 2017
P1b, N=36, Active, not recruiting, Sponsor: Amgen
Recruiting --> Suspended Trial primary completion date: Aug 2017 --> Apr 2017
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=1, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2017 --> Apr 2017 N=20 --> 1
- Synribo (omacetaxine mepesuccinate) / Teva
Trial termination, Trial primary completion date: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 26, 2017
P2, N=2, Terminated, Sponsor: M.D. Anderson Cancer Center
N=20 --> 1 Active, not recruiting --> Terminated | Trial primary completion date: May 2018 --> Jun 2017; Slow Accrual-2 patients were registered Phase I and none in Phase II
- | deferasirox tablet for oral suspension / Generic mfg.
Phase classification: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 20, 2017
P2, N=16, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Terminated | Trial primary completion date: May 2018 --> Jun 2017; Slow Accrual-2 patients were registered Phase I and none in Phase II Phase classification: P=N/A --> P2
- | NN1213 / Novo Nordisk
Trial completion: HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (clinicaltrials.gov) - Jun 19, 2017
P2, N=40, Completed, Sponsor: St. Jude Children's Research Hospital
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 19, 2017
P=N/A, N=90, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Jan 2017
- | indisulam (E7070) / Eisai
Trial completion, Trial primary completion date: E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 15, 2017
P2, N=43, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2017 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2019 --> Jun 2017
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change, Metastases: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=100, Completed, Sponsor: University of Illinois at Chicago
Active, not recruiting --> Completed | Trial primary completion date: Feb 2019 --> Jun 2017 N=152 --> 100
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment open, Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 14, 2017
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
N=152 --> 100 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019
- | Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 14, 2017
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019 Active, not recruiting --> Recruiting
- || RG6146 / Roche
Enrollment change, Trial primary completion date: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 14, 2017
P1, N=51, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting N=37 --> 51 | Trial primary completion date: Aug 2017 --> Jan 2018
- Farydak (panobinostat) / Secura Bio
Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 12, 2017
P1, N=28, Active, not recruiting, Sponsor: University of California, San Francisco
N=37 --> 51 | Trial primary completion date: Aug 2017 --> Jan 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- | Enrollment change, Trial termination, Trial primary completion date: Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 9, 2017
P=N/A, N=2, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2015 --> Dec 2016 N=10 --> 2 | Suspended --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2015; Updating protocol and consents
- | Phase classification, Enrollment change, Trial termination, Trial primary completion date: Observational Trial of a Therapeutic Platelet Transfusion Regimen (clinicaltrials.gov) - Jun 8, 2017
P=N/A, N=25, Terminated, Sponsor: Klinikum N
N=10 --> 2 | Suspended --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2015; Updating protocol and consents Phase classification: P4 --> P=N/A | N=120 --> 25 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jun 2017; Insufficient recruitment
- Ninlaro (ixazomib) / Takeda
Trial termination, Trial primary completion date: Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission (clinicaltrials.gov) - Jun 5, 2017
P2, N=5, Terminated, Sponsor: M.D. Anderson Cancer Center
Phase classification: P4 --> P=N/A | N=120 --> 25 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jun 2017; Insufficient recruitment Active, not recruiting --> Terminated | Trial primary completion date: Mar 2021 --> May 2017; Slow Accrual
- | Onureg (azacitidine oral) / BMS
Trial completion: Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=30, Completed, Sponsor: Celgene
Active, not recruiting --> Terminated | Trial primary completion date: Mar 2021 --> May 2017; Slow Accrual Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD), Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Combination therapy: Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2017
P2, N=31, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=107 --> 31
- ||| Trial completion, Minimal residual disease: MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2017
P=N/A, N=150, Completed, Sponsor: Center for International Blood and Marrow Transplant Research
N=107 --> 31 Active, not recruiting --> Completed
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - May 30, 2017
P2, N=71, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - May 30, 2017
P2, N=30, Suspended, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011 Phase classification: P=N/A --> P2
- | Trial primary completion date: GIMEMAAML1310: Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 24, 2017
P2, N=237, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase classification: P=N/A --> P2 Trial primary completion date: Dec 2016 --> Jul 2017
- | Trial completion, Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=9, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2016 --> Jul 2017 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- | Trial completion: Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2017
P=N/A, N=40, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Not yet recruiting --> Completed
- Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Monotherapy: Study of Ibrutinib in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2017
P2a, N=36, Terminated, Sponsor: Pharmacyclics LLC.
Not yet recruiting --> Completed N=101 --> 36 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Feb 2017; Study data do not support development in AML.
- | Biomarker, Trial completion, Adverse events: Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=257, Completed, Sponsor: Eastern Cooperative Oncology Group
N=101 --> 36 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Feb 2017; Study data do not support development in AML. Not yet recruiting --> Completed
- | Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=220, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012
- | Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=30, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012 Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009
- | cytarabine / Generic mfg.
Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy (clinicaltrials.gov) - May 17, 2017
P=N/A, N=200, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009 Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010
- | Trial completion, Enrollment change, Trial primary completion date: Transfusional Iron Overload Among Leukemia Survivors (clinicaltrials.gov) - May 16, 2017
P=N/A, N=24, Completed, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010 Recruiting --> Completed | N=61 --> 24 | Trial primary completion date: Nov 2018 --> May 2017
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Combination therapy: Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2017
P1, N=60, Recruiting, Sponsor: Bhavana Bhatnagar
Recruiting --> Completed | N=61 --> 24 | Trial primary completion date: Nov 2018 --> May 2017 Suspended --> Recruiting
- | FLX925 / RAPT Therap
Enrollment closed: First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 3, 2017
P1, N=123, Active, not recruiting, Sponsor: FLX Bio, Inc.
Suspended --> Recruiting Recruiting --> Active, not recruiting
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial completion, Metastases: Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies (clinicaltrials.gov) - May 3, 2017
P1/2, N=49, Completed, Sponsor: Prism Pharma Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- navtemadlin (KRT-232) / Kartos Therap
Enrollment closed, Enrollment change, Combination therapy: A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 28, 2017
P1b, N=36, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=130 --> 36
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial primary completion date: Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 28, 2017
P1, N=33, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=130 --> 36 Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Apr 2017
- | lithium carbonate ER / Generic mfg.
Trial completion, Enrollment change: Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2017
P1, N=12, Completed, Sponsor: Paolo Caimi, MD
Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Apr 2017 Active, not recruiting --> Completed | N=24 --> 12
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (clinicaltrials.gov) - Apr 27, 2017
P2, N=6, Recruiting, Sponsor: Celator Pharmaceuticals
Active, not recruiting --> Completed | N=24 --> 12 Trial primary completion date: Dec 2016 --> Jun 2017
- ||||||| azacitidine / Generic mfg.
Trial completion: Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 26, 2017
P3, N=488, Completed, Sponsor: Celgene
Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed
- Xospata (gilteritinib) / Astellas
Enrollment change: Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 26, 2017
P1, N=24, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed N=36 --> 24
- | Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 20, 2017
P1, N=35, Recruiting, Sponsor: University of Southern California
N=36 --> 24 Trial primary completion date: Mar 2016 --> Mar 2018
- | cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Trial primary completion date: Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 19, 2017
P1, N=53, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Mar 2016 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015
- | Simulect (basiliximab) / Novartis
Trial primary completion date, IO biomarker: Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (clinicaltrials.gov) - Apr 19, 2017
P1, N=36, Active, not recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015 Trial primary completion date: Mar 2017 --> Dec 2017
- | dapsone / Generic mfg.
Enrollment change: Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=41, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Mar 2017 --> Dec 2017 N=200 --> 41
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial suspension: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=30, Suspended, Sponsor: Wake Forest University Health Sciences
N=200 --> 41 Recruiting --> Suspended
- | Januvia (sitagliptin) / Merck (MSD)
Enrollment closed, Enrollment change: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Apr 11, 2017
P2, N=19, Active, not recruiting, Sponsor: Sherif S. Farag
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=74 --> 19